Eifa AC granules 600mg, No. 10

Diseases of the respiratory system and conditions accompanied by the formation of viscous and mucopurulent sputum: acute and chronic bronchitis, tracheitis due to bacterial and / or viral infection, pneumonia, bronchiectasis, bronchial asthma, atelectasis due to bronchial obstruction by a mucous plug, sinusitis (to facilitate secretion discharge ), cystic fibrosis (as part of combination therapy).

Preparation for bronchoscopy, bronchography, aspiration drainage.

Removal of viscous secretions from the respiratory tract in post-traumatic and postoperative conditions.

For washing abscesses, nasal passages, maxillary sinuses, middle ear, treatment of fistulas, surgical field during operations on the nasal cavity and mastoid process.

Inside for adults and children over 6 years old - 200 mg 2-3 times / day; children aged 2 to 6 years - 200 mg 2 times / day or 100 mg 3 times / day.

For inhalation and intratracheal administration, the dose, frequency of use and duration of the course are set individually.

Locally - 150-300 mg are instilled into the external auditory canal and nasal passages for 1 procedure.

Granules for the preparation of a solution for oral administration, white or almost white, homogeneous, irregular, without agglomerates, with a characteristic odor.

acetylcysteine ??600 mg

Peptic ulcer and duodenal ulcer in the acute phase, hemoptysis, pulmonary hemorrhage, lactation (breastfeeding), children under 2 years of age, hypersensitivity to acetylcysteine.

Contraindications for use in children under the age of 14 years depend on the dosage form and are indicated in the instructions for use of the drug used.

pharmachologic effect

Mucolytic agent is a derivative of the amino acid cysteine. It has a mucolytic effect, increases the volume of sputum, facilitates its discharge due to a direct effect on the rheological properties of sputum. The action of acetylcysteine ??is associated with the ability of its sulfhydryl groups to break intra- and intermolecular disulfide bonds of acidic mucopolysaccharides of sputum, which leads to depolarization of mucoproteins and a decrease in sputum viscosity.

Reduces induced hyperplasia of mucoid cells, enhances the production of surface active compounds by stimulating type II pneumocytes, stimulates mucociliary activity, which leads to an improvement in mucociliary clearance.

Remains active in the presence of purulent, mucopurulent and mucous sputum.

Increases the secretion of less viscous sialomucins by goblet cells, reduces the adhesion of bacteria on the epithelial cells of the bronchial mucosa. Stimulates the mucous cells of the bronchi, the secretion of which lyses fibrin. It has a similar effect on the secretion formed in inflammatory diseases of the upper respiratory tract.

It has an antioxidant effect due to the ability of its reactive sulfhydryl groups (SH-groups) to bind to oxidative radicals and thus neutralize them.

Acetylcysteine ??easily penetrates into the cell, deacetylated to L-cysteine, from which intracellular glutathione is synthesized. Glutathione is a highly reactive tripeptide, a powerful antioxidant and cytoprotector that neutralizes endogenous and exogenous free radicals and toxins. Acetylcysteine ??prevents depletion and increases the synthesis of intracellular glutathione, which is involved in the redox processes of cells, contributing to the detoxification of harmful substances. This explains the action of acetylcysteine ??as an antidote for paracetamol poisoning.

Protects alpha1-antitrypsin (elastase inhibitor) from the inactivating effect of HOCI, an oxidant produced by myeloperoxidase of active phagocytes. It also has an anti-inflammatory effect (by suppressing the formation of free radicals and active oxygen-containing substances responsible for the development of inflammation in the lung tissue).

Pharmacokinetics

When taken orally, it is well absorbed from the gastrointestinal tract. To a large extent undergoes the effect of the 'first pass' through the liver, which leads to a decrease in bioavailability. Binding to blood plasma proteins up to 50% (4 hours after oral administration). It is metabolized in the liver and possibly in the intestinal wall. In plasma, it is determined unchanged, as well as in the form of metabolites - N-acetylcysteine, N, N-diacetylcysteine ??and cysteine ??ester.

Renal clearance is 30% of the total clearance.

Indications of active substances of the drug Eifa AC

Diseases of the respiratory system and conditions accompanied by the formation of viscous and mucopurulent sputum: acute and chronic bronchitis, tracheitis due to bacterial and / or viral infection, pneumonia, bronchiectasis, bronchial asthma, atelectasis due to bronchial obstruction by a mucous plug, sinusitis (to facilitate secretion discharge ), cystic fibrosis (as part of combination therapy).

Preparation for bronchoscopy, bronchography, aspiration drainage.

Removal of viscous secretions from the respiratory tract in post-traumatic and postoperative conditions.

For washing abscesses, nasal passages, maxillary sinuses, middle ear, treatment of fistulas, surgical field during operations on the nasal cavity and mastoid process.

Side effect

Allergic reactions: urticaria, rash, itching, angioedema, anaphylactic reactions, facial edema.

From the nervous system: headache.

On the part of the organ of hearing and balance: tinnitus.

From the side of the cardiovascular system: tachycardia, lowering blood pressure, bleeding

From the respiratory system: bronchospasm, dyspnea.

From the digestive system: vomiting, diarrhea, stomatitis, abdominal pain, nausea, dyspepsia.

General reactions: pyrexia.

Contraindications for use

Peptic ulcer and duodenal ulcer in the acute phase, hemoptysis, pulmonary hemorrhage, lactation (breastfeeding), children under 2 years of age, hypersensitivity to acetylcysteine.

Contraindications for use in children under the age of 14 years depend on the dosage form and are indicated in the instructions for use of the drug used.

Application during pregnancy and lactation

If necessary, use during pregnancy should carefully weigh the expected benefits of therapy for the mother and the possible risk to the fetus.

Use during lactation (breastfeeding) is contraindicated.

Application for violations of liver function

Acetylcysteine ??is used with caution in patients with liver disease.

Application for impaired renal function

Acetylcysteine ??is used with caution in patients with kidney disease.

Application in children

When using acetylcysteine ??in patients with bronchial asthma, it is necessary to ensure drainage of sputum. In newborns, it is used only for health reasons at a dose of 10 mg / kg under the strict supervision of a physician.

Inside for children over 6 years old - 200 mg 2-3 times / day; children aged 2 to 6 years - 200 mg 2 times / day or 100 mg 3 times / day, up to 2 years - 100 mg 2 times / day.

special instructions

Use with caution in the following diseases and conditions: a history of gastric ulcer and duodenal ulcer; bronchial asthma, hepatic and / or renal failure; histamine intolerance (long-term use should be avoided, because acetylcysteine ??affects the metabolism of histamine and can lead to signs of intolerance, such as headache, vasomotor rhinitis, itching); varicose veins of the esophagus; diseases of the adrenal glands; arterial hypertension.

When using acetylcysteine ??in patients with bronchial asthma, it is necessary to ensure drainage of sputum.

A 1-2 hour interval should be observed between taking acetylcysteine ??and antibiotics.

Compliance with the route of administration and the dosage form used should be strictly observed.

Drug interactions

The simultaneous use of acetylcysteine ??with antitussives can increase sputum congestion due to suppression of the cough reflex.

With simultaneous use with antibiotics (including tetracycline, ampicillin, amphotericin B), their interaction with the thiol group of acetylcysteine ??is possible.

The simultaneous intake of acetylcysteine ??and nitroglycerin can cause a marked decrease in blood pressure and headache.

The simultaneous use of acetylcysteine ??and carbamazepine may be accompanied by a decrease in the concentration of carbamazepine to the subtherapeutic level.

Acetylcysteine ??eliminates the toxic effects of paracetamol.

Acetylcysteine ??can interfere with the colorimetric determination of salicylates.

Acetylcysteine ??may interfere with urine ketone test results.